Prognostic value of cytosolyc cathepsin D content in resectable gastric cancer

Casar, José M. del; Vizoso, F; Abdel-Laa, Omar; Sanz, Lourdes; Martin, Adam P.; Corte, M.D.; Bongera, Miguel; Muñiz, J.L.; Fueyo, Antonio

doi:10.1002/jso.20041

Cited by 6 publications

(4 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the present study we have evaluated the potential relationship between LBVI and several new biological parameters from gastric carcinomas recently associated with tumoral aggressiveness and poor prognosis, such as the tyrosine kinase receptors c-erbB-2 (Garcia et al 2003a;Vizoso et al 2004b) and EGFR (Garcia et al 2003b), the proteolytic enzymes cathepsin D (Manuel Del Casar et al 2004) and tPA (Raigoso et al 2000), the spasmolytic peptide pS2 (Suarez et al 2001;Dhar et al 2003) or the extracellular proteoglycan hyaluronic acid (Vizoso et al. 2004a).…”

Section: Discussionmentioning

confidence: 99%

Lymphatic and/or blood vessel invasion in gastric cancer: relationship with clinicopathological parameters, biological factors and prognostic significance

Casar

Corte

Alvarez

et al. 2007

J Cancer Res Clin Oncol

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Lymphatic and/or blood vessel invasion in gastric cancer: relationship with clinicopathological parameters, biological factors and prognostic significance

Casar

Corte

Alvarez

et al. 2007

J Cancer Res Clin Oncol

Self Cite

View full text Add to dashboard Cite

show abstract

“…Although we have yet to complete the validation that the other six proteins using the same approach as described for CK19, a brief review of the published literature suggest their potential involvement in breast tumor development [39][40][41][42][43][44][45][46][47][48][49][50][51][52][53][54]. Our research on breast cancer has been prioritized to confirm this concept experimentally and to define the functions of these proteins and to study their interrelationship in the malignant breast tissue microenvironment.…”

Section: Discussionmentioning

confidence: 99%

“…Cathepsin D is up-regulated in many types of tumorigenesis [48] and down-regulated in a hepatoma revertant cell line [49]. Patients with lower levels of cathepsin D had better survival rates than those with intermediate or high cathepsin D tumor content [50]. Ikeguchi et al [51] reported that cathepsin D expression is associated with p53 abnormality in oesophageal squamous cell carcinoma.…”

Section: Discussionmentioning

confidence: 99%

Proteomics of breast cancer: Enhanced expression of cytokeratin19 in human epidermal growth factor receptor type 2 positive breast tumors

Zhang¹,

Tai²,

Wong

et al. 2005

Proteomics

View full text Add to dashboard Cite

The human epidermal growth factor receptor, type 2 (HER-2/neu or c-erbB-2) is a 185 kDa transmembrane protein that is phosphorylated upon ligand binding and dimerization with members of the HER/c-erbB family and regulates cell growth and differentiation. Its overexpression is strongly associated with advanced disease, metastasis and poor clinical outcome. To better understand the mechanisms underlying the poor prognosis of breast tumors with HER-2/neu-positive status, parallel proteomic analyses were performed on estrogen receptor-negative and node-positive breast tumors with or without overexpression of the HER-2/neu oncogene, using laser capture microdissection and two-dimensional gel electrophoresis. The differentially expressed proteins were identified by peptide mass fingerprinting using matrix-assisted laser desorption/ionization-time of flight mass spectrometry. Cytokeratin 19 (CK19), one of the identified proteins, was highly expressed in the HER-2/neu-positive breast tumors when compared with HER-2/neu-negative breast tumors. The enhanced overexpression of CK19 in HER-2/neu-positive tumors was further analyzed using semiquantitative reverse-transcription polymerase chain reaction, Western blotting and reverse-phase protein arrays. Immunohistochemical staining of sections from a breast tumor tissue microarray of 97 tumors showed moderate to strong staining against anti-CK19 antibody in 20 (5 with moderate and 15 with strong staining) of the 26 HER-2/neu-positive tumors (76.9%) and in 22 (12 with moderate and 10 with strong staining) of 52 HER-2/neu-negative tumors (48%) (p = 0.002). Our results indicate that CK19, an intermediate fragment of the cytoskeleton, and other proteins showing differential expression, are likely to be intricately involved in intra- and intercellular molecular events driving the more aggressive tumor proliferation, invasion and metastasis associated with HER-2/neu-positive tumors.

show abstract

“…Cathepsin D (CATD) was the best performing variable (AUC: 0.648) out of them. The level of CATD in gastric carcinomas represents poor prognosis 26 . NCAM1 (CD56) is a well-known surface marker of immune cells.…”

Section: Discussionmentioning

confidence: 99%

SEPROGADIC – serum protein-based gastric cancer prediction model for prognosis and selection of proper adjuvant therapy

Ahn

Sohn

Kim

et al. 2018

Sci Rep

View full text Add to dashboard Cite

Gastric cancer (GC) patients usually receive surgical treatment. Postoperative therapeutic options such as anticancer adjuvant therapies (AT) based on prognostic prediction models would provide patient-specific treatment to decrease postsurgical morbidity and mortality rates. Relevant prognostic factors in resected GC patient’s serum may improve therapeutic measures in a non-invasive manner. In order to develop a GC prognostic model, we designed a retrospective study. In this study, serum samples were collected from 227 patients at a 4-week recovery period after D2 lymph node dissection, and 103 cancer-related serum proteins were analyzed by multiple reaction monitoring mass spectrometry. Using the quantitative values of the serum proteins, we developed SEPROGADIC (SErum PROtein-based GAstric cancer preDICtor) prognostic model consisting of 6 to 14 serum proteins depending on detailed purposes of the model, prognosis prediction and proper AT selection. SEPROGADIC could clearly classify patients with good or bad prognosis at each TNM stage (1b, 2, 3 and 4) and identify a patient subgroup who would benefit from CCRT (combined chemoradiation therapy) rather than CTX (chemotherapy), or vice versa. Our study demonstrated that serum proteins could serve as prognostic factors along with clinical stage information in patients with resected gastric cancer, thus allowing patient-tailored postsurgical treatment.

show abstract

Prognostic value of cytosolyc cathepsin D content in resectable gastric cancer

Abstract: The present study demonstrates the presence of higher Cath-D content in gastric carcinomas than in adjacent non-neoplastic mucosa, and that high intratumor Cath-D levels identify a subgroup of resectable gastric cancer patients with a high probability of relapse as well as worse survival.

Cited by 6 publications

References 23 publications

Lymphatic and/or blood vessel invasion in gastric cancer: relationship with clinicopathological parameters, biological factors and prognostic significance

Lymphatic and/or blood vessel invasion in gastric cancer: relationship with clinicopathological parameters, biological factors and prognostic significance

Proteomics of breast cancer: Enhanced expression of cytokeratin19 in human epidermal growth factor receptor type 2 positive breast tumors

SEPROGADIC – serum protein-based gastric cancer prediction model for prognosis and selection of proper adjuvant therapy

Contact Info

Product

Resources

About